Stock PTCT PTC THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-03 EDT 		5-day change 1st Jan Change
33.01 USD -1.81% Intraday chart for PTC Therapeutics, Inc. +15.54% +19.78%
04-30 North American Morning Briefing : More Earnings -2- DJ
04-29 Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28 MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PTC Therapeutics : Corporate Presentation – May 2024
PU
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR
PTC Therapeutics : Q1 2024 FLS
PU
PTC Therapeutics: Q1 Earnings Snapshot
AQ
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PR
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
AQ
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
PR
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
PR
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency
AQ
PTC Therapeutics Provides Key Regulatory Updates
PR
PTC Therapeutics: Q4 Earnings Snapshot
AQ
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
PR
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)
AQ
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
PR
PTC Therapeutics - CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna Following Re-examination Procedure
AQ
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PTCT Stock
  4. News PTC Therapeutics, Inc.
  5. Press Releases